Equity Overview
Price & Market Data
Price: $30.00
Daily Change: -$0.46 / 1.53%
Daily Range: $29.54 - $30.77
Market Cap: $1,807,202,176
Daily Volume: 103,119
Performance Metrics
1 Week: -0.10%
1 Month: 6.50%
3 Months: 43.75%
6 Months: 787.6%
1 Year: 519.8%
YTD: 30.38%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.